

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Bartnick et al.

Title:

METHOD FOR THE

PRODUCTION OF NATURAL

BOTANICAL EXTRACTS

Appl. No.:

10/706,309

Filing Date:


11/12/2003

Examiner:

Unknown

Art Unit:

1761



INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document, except as noted below, is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-2350. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-2350.

Respectfully submitted,

Date April 9, 2004

FOLEY & LARDNER LLP
Customer Number: 23524

Telephone:

(608) 258-4305

Facsimile:

(608) 258-4258

Michelle Manning

Attorney for Applicant Registration No. 50,592

Form PTO-1449
U.S. DEPARTMENT OF COMMERCE
(MODIFIED)
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION
Date Filed: April 9, 2004

FILING DATE

TAKEN OF THE PTO-1449

ATTY. DOCKET NO.

081583:0291
10/766,309

APR 1 2 2004

FILING DATE

GROUP ART ONIT

Use several sheets if peessens)					FILING DATE		GROUP ART ONT	
· (Use several sheets if necessary)				11/12/2003			1761 LODAN	
	, 		U.S. P.	ATEN	T DOCUMENTS			
EXAMINER INITIAL			DATE		NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
		497,546	5/16/1893	de L	airr			***
		1,010,043	11/28/1911	Gov	en			
		1,515,714	11/18/1924	Wus	sow			
		2,051,017	8/11/1936	Sch	warz			
		2,506,540	5/2/1950	Brya	ın			
		2,745,796	5/15/1956	Top	pel			
		2,835,591	5/20/1958	Grav	es, et al.			_
		3,112,204	11/26/1963	Yani	ck			
		3,640,725	2/8/1972	She	ba, et al.			
		4,123,559	10/31/1978	Vitzt	hum, et al.			
	1	4,198,432	4/15/1980	Vitzt	hum, et al.		17/1	
		4,204,043	5/20/1980	Sch	ıltz			
		4,333,955	6/8/1982	Mura	nta, et al.			
		4,470,927	9/11/84	Schu	ıtz, et al.	-		
		4,474,994	10/2/1984	Maki	n			
		4,490,398	12/25/84	Behr	, et al.			
		4,632,837	12/30/1986	Schu	ıtz, et al.			::
		4,847,422	7/11/1989	Klen	iola, et al.			
		4,898,990	2/6/1990	Coe	nen, et al.			
		4,946,695	8/7/1990	Fors	ter, et al.			
		4,981,699	1/1/1991	Inad	a, et al.			
		5,017,388	5/21/1991	Rab	enhorst, et al.		_	
		5,068,184	11/26/1991	Knut	h, et al.			
		5,096,719	3/17/1992	Gres	ch		-	
		5,120,558	6/9/1992	Ngu	/en, et al.			
		5,151,188	9/29/1992	Hop	per, et al.			
		5,298,265	3/29/1994	Poul	ose, et al.			
		5,358,861	10/25/1994	Mark	us, et al.			
		5,362,503	11/8/1994	Burri	, et al.			
	-	5,705,205	1/6/1998	Brun	erie			
		5,891,493	4/6/1999	Sant	illo, Jr.			
		5,891,504	4/6/1999	Knut	h, et al.		 	

	5,895,657	4/20/1999	Fournet, et al.			
	5,902,622	5/11/1999	Owusu-Ansah, et al.			
	5,919,500	7/6/1999	Lehmberg, et al.			
	5,925,389	7/20/1999	Lehmberg, et al.			
	5,952,023	9/14/1999	Lehmberg, et al.			
	5,958,474	9/28/1999	Lee, et al.			
	5,985,352	11/16/1999	Todd			
	6,013,289	1/11/2000	Blank, et al.			
	6,024,990	2/15/2000	Kofoed, et al.			
	6,024,991	2/15/2000	Lehmberg, et al.			
	6,033,692	3/7/2000	Chukwu			
	6,099,844	8/8/2000	Rhode, Jr., et al.			
	6,129,937	10/10/2000	Zurbriggen, et al.			
	6,203,837	3/20/2001	Kalenian	·		
	6,235,507	5/22/2001	Muheim, et al.			
	6,428,828	8/6/2002	Jackson, et al.			
	6,548,094	4/15/2003	Kalenian			
	6,610,343	4/26/2003	Purtle et al.			
	2001/0000145	4/5/2001	Kalenian			
	2001/0014467	8/16/2001	Narbad, et al.			
	2002/0187245	12/12/2002	McFadden, et al.			
	2003/0070188	5/15/2003	Havkin-Frenkel, et al.			
	2003/0092143	5/15/2003	Rabenhorst, et al.			
	2003/0092168	2/15/2003	Lubrano, et al.			
	2003/0118707	6/26/2003	Kalenian			
	OTHER DOCU	MENTS (Includ	ling Author, Title, Date, Pe	ertinent Pages, Etc.)		
		cal Bulletin - Nun	nber 110, "The Use of Enzym	•	" 2 pages,	
_						
MINER			DATE CONSIDE	DATE CONSIDERED		
EXAMINE	R: Initial if citation	considered, v	whether or not citation is	s in conformance wi	th MPEP 609: Dr	
			and not considered. I			